Graybug Vision’s $80 Million Series C Financing

Fenwick & West represented Graybug Vision in the transaction.

Graybug Vision is a clinical-stage pharmaceutical company developing therapies for ocular diseases. The company’s proprietary injectable products are designed to enable less frequent administration to reduce the burden of treatment for patients and their physicians.

CBC Group (formerly C-Bridge Capital) led the Series C financing, with participation from existing investors Deerfield Management, OrbiMed Advisors, Hatteras Venture Partners, a fund managed by Blackstone Life Sciences and other new investors.

Graybug Vision will use the funding to advance its retina and glaucoma clinical programs.

Fenwick represented Graybug Vision with a team led by corporate partners Effie Toshav (Picture) and Michael Brown and associates Julia Forbess and Elliot Ginsburg.

Involved fees earner: Michael Brown – Fenwick & West LLP; Julia Forbess – Fenwick & West LLP; Elliot Ginsburg – Fenwick & West LLP; Effie Toshav – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: Graybug Vision;

Author: Ambrogio Visconti